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Leeds, York, Birmingham, Middlesbrough, Southampton, and London, United KingdomObjectives The goal of this study was to report outcomes from percutaneous coronary intervention
(PCI) to an unprotected left main stem (UPLMS) stenosis according to presenting syndrome,
including ST-segment elevation myocardial infarction (STEMI), non–ST-segment elevation acute
coronary syndrome (NSTEACS), and chronic stable angina (CSA).
Background There are no published whole-country data concerning patient outcomes following PCI
to UPLMS.
Methods This study is a prospective national cohort study using data from the British Cardiovascular
Intervention Society (BCIS) registry from January 1, 2005, through December 31, 2010.
Results Of 5,065 patients having PCI to an UPLMS, 784 (15.5%) presented with STEMI, 2,381 (47.0%)
with NSTEACS, and 1,900 (37.5%) with CSA. Crude 30-day and 1-year mortality rates were STEMI:
28.3% and 37.6%, NSTEACS: 8.9% and 19.5%, and CSA: 1.4% and 7.0%, respectively. Unadjusted in-
hospital major adverse cardiovascular and cerebrovascular event rates were STEMI: 26.6%, NSTEACS:
6.6%, and CSA: 3.3%. Risk of 30-day mortality was much greater for STEMI and NSTEACS patients than
CSA (STEMI adjusted odds ratio [aOR]: 29.45, 95% conﬁdence interval [CI]: 19.37 to 44.80, NSTEACS aOR:
6.45, 95% CI: 4.27 to 9.76). More than 40% of patients presenting with STEMI had cardiogenic shock, in
whom mortality was higher than in STEMI cases without shock (30 days: 52.0% vs. 11.7%, 1 year: 61.1%
vs. 20.9%). Radial access, compared with the femoral approach, was associated with a lower risk of
30-day mortality (STEMI aOR: 0.37, 95% CI: 0.21 to 0.62; NSTEACS aOR: 0.66, 95% CI: 0.45 to 0.97).
Conclusions More than one-half of the patients who received UPLMS PCI were acute where
outcomes were much worse than elective cases. Cardiogenic shock is common in STEMI patients,
of whom more than one-half die at 30 days. The radial approach was associated with reduced early
mortality in acute cases. (J Am Coll Cardiol Intv 2014;7:717–30) ª 2014 by the American College of
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718Coronary artery bypass grafting (CABG) has been the
standard of care for the management of left main stem
(LMS) disease (1–5). In contemporary practice, however,
percutaneous coronary intervention (PCI) has become an
alternative strategy in patients who have unprotected left
main stem (UPLMS) disease, particularly in those deemedSee page 731at high risk for surgery (6), even though repeat revasculari-
zation procedures are increased with LMS PCI compared
with CABG (2). Notably, higher rates of success are not#National Institute for Cardiovascul
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Abbreviations
and Acronyms
aOR = adjusted odds ratio
BCIS = British Cardiovascular
Intervention Society
CABG = coronary artery
bypass grafting
CI = conﬁdence interval
CSA = chronic stable angina
IABP = intra-aortic balloon
pump
IVUS = intravascular
ultrasound
LVSD = left ventricular
systolic dysfunction
MACCE = major adverse
cardiovascular and
cerebrovascular event(s)
NSTEACS = non–ST-segment
elevation acute coronary
syndrome
PCI = percutaneous coronary
intervention
STEMI = ST-segment
elevation myocardial
infarction
UPLMS = unprotected left
main stemconﬁned to elective patients with
chronic stable angina (CSA),
and favorable outcomes have
been reported in emergency cases
when CABG is often contra-
indicated (7–9). Yet, for patients
who receive PCI to disease of the
UPLMS, there is a paucity of
data that measure outcomes in
unselected patients on a large
scale and in a consecutive series.
There is, therefore, value in
reporting contemporary and re-
presentative outcomes data for
PCI to the UPLMS in order to
inform patients, healthcare pro-
fessionals, and regulators of both
the beneﬁts and inherent risks
of such therapy, and also to
highlight areas where novel in-
terventions aimed at impro-
ving outcomes may be targeted
(7,10–15). Moreover, there is a
gap in the knowledge base
regarding the relative merits of
PCI to an UPLMS culprit lesion
in patients who present with
ST-segment elevation myocardial
infarction (STEMI) or non–ST-segment elevation acute coronary syndrome (NSTEACS)
(16). For patients with cardiogenic shock, there are very limited
data available in the published reports, with early outcomes
reported in only small “hypothesis-generating” cohort studies.
Similarly, although recent international guidelines recommendar Outcomes Research (NICOR), University
gdom. The British Cardiovascular Intervention
the Health Quality Improvement Partnership
tional Institute for Health Research (NIHR/CS/
onorary Consultant Cardiologist. Dr. Baxter is
Funding Council for England (HEFCE). Dr.
nts from Haemonetics, St. Jude Medical, and
and on the Speakers’ Bureaus of Haemonetics,a radial approach to PCI over that of the femoral approach
(17), the wider implications of this have not been studied in
patients who receive PCI to disease of the UPLMS.
The British Cardiovascular Intervention Society (BCIS)
registry is a prospective whole-country registry of all PCIs
in adults that has collected patient-level data from all centers
in the United Kingdom since 2005. It provides data that
cannot be collected within a randomized controlled trial, and
few cohort studies have comparable population coverage,
long-term follow-up, and depth of data detail in relation to
clinical risk. The primary aim of this study was to perform a
population-based comparative investigation into the clinical
outcomes of patients who received PCI to an UPLMS
stenosis, according to clinical syndrome at presentation. Our
secondary aims were: 1) to quantify the impact of cardio-
genic shock; and 2) to report the impact of the radial versus
femoral approach on outcomes by clinical presentation.
Methods
Setting and design. This study was on the basis of data from
the BCIS audit program, in which participation is mandated
for all PCI operators and all hospitals in the United Kingdom
(18). Data for every PCI procedure performed were collected
prospectively at each hospital. These data were then encrypted
and transferred securely online to a central database, using a
system developed by the Central Cardiac Audit Database,
now part of the National Institute for Cardiovascular
Outcomes Research (NICOR). The data for each PCI pro-
cedure comprise 113 core ﬁelds that describe the patient
demographics and clinical presentation, indications for PCI,
procedural details, and outcomes during the hospital stay (19).
Patients, procedures, and treatments. Although BCIS col-
lects data from all countries in the United Kingdom, robust
mortality tracking is only available for patients who live in
England and Walesdthis represents approximately 89% of
the U.K. population. Thus, the sampling frame comprised
all patients in England and Wales. Patients were eligible for
the UPLMS analyses if they had received PCI to a diseased
UPLMS during a 6-year period between January 1, 2005,
and December 31, 2010, and were at least 18 years of age.
These patients were drawn from those who had the left main
stem as the treated vessel. Patients with an UPLMS were
deﬁned as those who did not have a patent graft to any left-
sided coronary artery (18). For those with multiple admis-
sions, we used the earliest record.Boston Scientiﬁc, St. Jude Medical, Daiichi Sankyo, and Abbott Vascular. The National
Institute for Cardiovascular Outcomes Research (NICOR), which hosts the BCIS
registry (Ref: NIGB: ECC 1-06 (d)/2011), has support under section 251 of the
National Health Service (NHS) Act 2006. Ethical approval was not required under
NHS research governance arrangements for the project. All other authors have reported
that they have no relationships relevant to the contents of this paper to disclose.
Manuscript received June 20, 2013; revised manuscript received March 8, 2014,
accepted March 13, 2014.
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719We deﬁned 3 strata, STEMI, NSTEACS, and CSA,
according to the mode of clinical presentation. The
consensus document of the Joint European Society of Car-
diology/American College of Cardiology was used as the
diagnostic standard for acute myocardial infarction
(AMI) and provided the basis for categorization by
the local supervising cardiologist into STEMI and
NSTEACS groups, according to the clinical presentation,Figure 1. Flow Chart of the Data
LMS ¼ left main stem; PCI ¼ percutaneous coronary intervention; UPLMS ¼ unproteelectrocardiogram, and troponin level where appropriate
(20). The STEMI group included patients receiving primary
PCI, rescue PCI, PCI for reinfarction, and facilitated PCI
for STEMI. Cardiogenic shock was deﬁned as a systolic
blood pressure <100 mm Hg and a pulse >100 beats/min in
a patient who was peripherally shut down and/or who
required inotropes, an intra-aortic balloon pump, or car-
diopulmonary support for the circulation (19).cted left main stem.
Table 1. Baseline Characteristics of Patients With UPLMS Disease Who Received PCI, by Clinical Presentation
CSA
(n ¼ 1,900)
STEMI
(n ¼ 784)
NSTEACS
(n ¼ 2,381)
Demographics and presentation
Age, yrs 68.9  11.3 67.3  13.7 72.2  12.1
Age >80 yrs 334/1,900 (17.6) 157/782 (20.1) 740/2,380 (31.1)
Male 1,350/1,869 (72.2) 568/780 (72.8) 1,565/2,361 (66.3)
IMD score 20.1  13.2 23.9  14.8 21.8  14.0
Medical history
Previous AMI 482/1,637 (29.4) 130/694 (18.7) 823/2,046 (40.2)
Previous PCI 539/1,892 (28.5) 73/764 (9.6) 429/2,338 (18.4)
Recent thrombolysis d 105/733 (14.3) 123/2,024 (6.1)
Family history of CAD 803/1,560 (51.5) 220/594 (37.1) 845/1,915 (44.1)
Diabetes mellitus 359/1,805 (19.9) 111/736 (15.1) 519/2,261 (23.0)
History of renal disease 80/1,774 (4.5) 30/690 (4.4) 216/2,205 (9.8)
Pre-procedural characteristics
Cardiogenic shock d 323/784 (41.2) 222/2,381 (9.3)
Severe LVSD (%) 118/1,298 (9.1) 148/334 (44.3) 318/1,635 (19.5)
LMS stenosis
0% 209/1,674 (12.5) 71/729 (9.7) 211/2,114 (10.0)
1%–49% 296/1,674 (17.7) 75/729 (10.3) 258/2,114 (12.2)
50% 1,169/1,674 (69.8) 583/729 (80.0) 1,645/2,114 (77.8)
Flow grade in IRA
TIMI 0 d 343/666 (51.5) 58/636 (9.1)
TIMI 1 d 89/666 (13.3) 40/636 (6.3)
TIMI 2 d 117/666 (17.6) 87/636 (13.7)
TIMI 3 d 117/666 (17.6) 451/636 (70.9)
Procedural characteristics
Vessels attempted
LMS only 569/1.883 (30.2) 186/781 (23.8) 649/2,371 (27.4)
Multivessels 1,314/1,883 (69.8) 595/781 (76.2) 1,722/2,371 (72.6)
Total number stents used
0 196/1,893 (10.4) 45/781 (5.8) 118/2,369 (5.0)
1 548/1,893 (28.9) 249/781 (31.9) 738/2,369 (31.1)
2 (%) 522/1,893 (27.6) 252/781 (32.2) 681/2,369 (28.8)
 3 (%) 627/1,893 (33.1) 235/781 (30.1) 832/2,369 (35.1)
Type of DES used
Taxus Liberté (Boston Scientiﬁc) 396/1,692 (21.8) 82/726 (11.3) 447/2,089 (21.4)
Cypher (Cordis) 159/1,692 (9.4) 45/726 (6.2) 169/2,089 (8.1)
Endeavor (Medtronic) 111/1,692 (6.6) 58/726 (8.0) 146/2,089 (7.0)
Xience V (Abbott Vascular) 171/1,692 (10.1) 79/726 (10.9) 214/2,089 (10.2)
Promus (Boston Scientiﬁc) 91/1,692 (5.4) 44/726 (6.1) 144/2,089 (6.9)
Arterial access
Femoral 1,243/1,864 (66.7) 526/768 (68.5) 1,497/2,348 (63.7)
Radial 580/1,864 (31.1) 231/768 (30.1) 791/2,348 (33.7)
Others 41/1,864 (2.2) 11/768 (1.4) 60/2,348 (2.6)
Continued on the next page
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720Follow-up and mortality. Analysis of all-cause mortality was
performed by the Medical Research Information System by
linkage with the Ofﬁce for National Statistics using each
patient’s unique National Health Service number. Using
their geographical residence, each patient’s Index of Multi-
ple Deprivation score was linked to their corresponding
BCIS record.Statistical analyses. Clinical outcomes were described with
and without adjustment. Adjustment for in-hospital major
adverse cardiovascular and cerebrovascular events (MACCE)
was undertaken using the factors age, sex, procedure urgency,
cardiogenic shock, left main stem PCI, graft PCI, history of
a stroke, and the corresponding published coefﬁcients from
the North West Quality Improvement Project (NWQIP)
Table 1. Continued
CSA
(n ¼ 1,900)
STEMI
(n ¼ 784)
NSTEACS
(n ¼ 2,381)
Post-procedural characteristics
LMS stenosis
0% 1,281/1,665 (76.9) 510/720 (70.9) 1,613/2,074 (77.8)
1%–49% 298/1,665 (17.9) 158/720 (21.9) 385/2,074 (18.6)
50% 86/1,665 (5.2) 52/720 (7.2) 76/2,074 (3.6)
Flow grade in IRA
TIMI 0 8/567 (1.4) 46/680 (6.8) 23/1,107 (2.0)
TIMI 1 2/567 (0.4) 26/680 (3.8) 3/1,107 (0.3)
TIMI 2 7/567 (1.2) 72/680 (10.6) 22/1,107 (2.0)
TIMI 3 550/567 (97.0) 536/680 (78.8) 1,059/1,107 (95.7)
Values are mean  SD or n/N (%).
AMI ¼ acute myocardial infarction; CAD ¼ coronary artery disease; CSA ¼ chronic stable angina; DES ¼ drug-eluting stent(s); IMD ¼ index of
multiple deprivation; IRA ¼ infarct-related artery; LMS ¼ left main stem; LVSD ¼ left ventricular systolic dysfunction; NSTEACS ¼ non–ST-segment
elevation acute coronary syndrome; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction;
TIMI ¼ Thrombolysis In Myocardial Infarction; UPLMS ¼ unprotected left main stem.
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721risk model (21). Cumulative unadjusted survival estimates
were depicted using the Kaplan-Meier method, and differ-
ences across strata compared using the Mantle-Cox log-rank
test. The associations with 30-day and 1-year mortality were
quantiﬁed using ﬁxed effects models, and estimates were
expressed as adjusted odds ratios (aOR) with 95% conﬁdence
intervals (CI). Each model estimate was standardized using
covariates selected after a published data review and in light
of the results of directed acyclic graphs and statistical corre-
lation. For all tests, a p value <5% was considered a cutoff
point for statistical signiﬁcance. All analyses were conducted
using Stata IC version 12.0 (StataCorp LP, College Station,
Texas).
Sensitivity analyses. We undertook a series of sensitivity
analyses to try to determine whether any of the following
may have biased the results. We evaluated the impact of
mixed effects models. Models were ﬁtted with a hierarchy of
patients clustered in each hospital (using random intercepts
for hospitals, thus allowing for correlations between patient
outcomes) and estimates compared with those from equiv-
alent ﬁxed effects models. Regression analyses were also
considered by complete cases and after imputation for
missing data. In total, 23 predictors of missing data were
selected that were on the basis of clinical consensus and a
published data review (3,10,13,15,22–25). The frequency of
missing values ranged from 0.04% to 58.4% and were
assumed to be missing at random. No data were missing for
1 of these variables, “clinical presentation,” though this
factor was still used in the imputation for the remaining 22
variables. Two other variables, “largest balloon/stent” and
“longest stented segment,” were not imputed because of
colinearity. A predictor matrix was designed on the basis
of clinical judgment as well as using thresholded p values of
<5% as related. For continuous–continuous and contin-
uous–categorical associations (continuous variables weremodeled as the response), linear regression was used,
whereas for categorical–categorical (including binary and
ordinal variables), the chi-square test was used. For each of
the 20 predictors with missing values, 20 datasets were
imputed using the chained equation method (26,27).
Continuous variables were imputed using predictive mean
matching, and the categorical data imputed using polyto-
mous regression. Finally, imputed datasets for each predictor
were pooled together using Rubin’s rule and followed by the
intended regressions. For each of the STEMI, NSTEACS,
and CSA groups, separate imputation datasets were created
for 30-day and 1-year mortality. Imputation diagnostics
were evaluated and did not give cause for concern.
Ethics. NICOR, which hosts the BCIS (Ref: NIGB: ECC
1-06 (d)/2011) dataset, has support under section 251 of the
NHS Act 2006. Under NHS research governance arrange-
ments, formal ethical approval was not required for this
study.
Results
A total of 10,410 patients received PCI to a LMS. Of these
5,065 (48.7%) had PCI to an UPLMS across 89 (78.1%)
hospitals in England and Wales (Fig. 1). The mean age
of the UPLMS PCI cohort was 70.2  12.3 years, and there
were 3,483 (69.5%) men. There were 784 (15.5%) patients
with STEMI, 2,381 (47.0%) with NSTEACS, and 1,900
(37.5%) with CSA. Because of the date of linkage for
censored data, mortality data at 1 year were not available for
519 (10.2%) patients.
Baseline clinical characteristics. There was a preponderance
of men in all groups. Table 1 shows the distribution
of baseline clinical characteristics by strata of clinical pre-
sentation. Diabetes mellitus, a family history of coronary
artery disease, previous PCI, and previous AMI were less
Figure 2. Kaplan-Meier Curves for Unadjusted Survival Time to All-Cause Mortality in Patients Who Received PCI to an UPLMS
The data are stratiﬁed by STEMI, NSTEACS, and CSA group from time of procedure to 6.6 years. The survival distributions of all 3 strata were signiﬁcantly different
(Mantle-Cox log rank test, p < 0.001). CSA ¼ chronic stable angina; NSTEACS ¼ non–ST-segment elevation acute coronary syndrome; STEMI ¼ ST-segment elevation
myocardial infarction; other abbreviations as in Figure 1.
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722frequent in STEMI patients. A history of chronic renal
failure was more frequent in patients with NSTEACS. In
total, 323 (41.2%) STEMI and 222 (9.3%) NSTEACS
patients presented with cardiogenic shock. Overall, the
frequency of severe left ventricular systolic dysfunction
(LVSD), deﬁned as a left ventricular ejection fraction
<30%, was 584 (17.9%), and was present in 148 (44.3%)Figure 3. Kaplan-Meier Curves for Unadjusted Survival Time to All-Cause Mortali
Who Received PCI to an UPLMS
Data are stratiﬁed by STEMI and NSTEACS group from time of procedure to 6.6 years
log rank test, p < 0.001). Abbreviations as in Figure 2.cases of STEMI. The proportion of missing data for
LVSD was 35.5%, reﬂecting the lack of a left ventricular
angiogram or urgent echocardiogram in the acute setting at
the time when the procedural part of the database was
completed.
Procedural characteristics. Femoral access was more
frequent than radial access (STEMI: 68.5% vs. 30.1%,ty in Patients With and Without Cardiogenic Shock
. The survival distributions of both strata were signiﬁcantly different (Mantle-Cox
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723NSTEACS: 63.7% vs. 33.7%), the former occurring more
frequently in STEMI and NSTEACS cases complicated
by cardiogenic shock (80.7% and 75.6%, respectively)
(Table 1). Multivessel PCI was frequent in each stratum
(STEMI: 76.2%, NSTEACS: 72.6%, and CSA: 69.8%).
Drug-eluting stents were deployed in 59.4% STEMI,
71.1% NSTEACS, and 77.8% CSA cases. When bare-
metal stents were used, they were deployed more
frequently in STEMI (STEMI: 35.8%, NSTEACS:
24.9%, CSA: 13.7%) patients. Of all stents, Taxus Liberté
(Boston Scientiﬁc, Natick, Massachusetts) were deployed
most often, in 925 (18.3%) cases, followed by Xience V
(Abbott Vascular, Santa Clara, California) in 464 (9.2%)
cases. An intravascular ultrasound (IVUS) was used more
frequently in elective than emergency cases (CSA: 35.9%,
STEMI: 14.6%, and NSTEACS: 30.1%). Pressure wire
assessment was performed in 12.0% of CSA, 0.6% of
STEMI, and 4.9% of NSTEACS cases. An intra-aorticTable 2. Clinical Outcomes of Patients With UPLMS Disea
CSA
n ¼ 1,
Procedural complication
Hemorrhage
Radial access 0/58
Femoral access 3/1,24
Side branch occlusion 17/1,71
Coronary dissection 106/1,71
Coronary perforation 13/1,71
DC cardioversion 6/1,71
No ﬂow/slow ﬂow 11/1,71
Ventilated 4/1,71
Cardiogenic shock (induced by procedure) 11/1,71
In-hospital outcomes
AMI 35/1,76
Stroke 0/1,76
Renal failure/dialysis 4/1,73
Blood transfusion
Radial access 0/58
Femoral access 4/1,24
GI bleeding
Radial access 0/58
Femoral access 1/1,24
Revascularization
PCI 5/1,80
CABG 5/1,80
Adjusted MACCE rates* 4.1 
Unadjusted mortality rates
7-day 19/1,90
30-day 27/1,90
6-month 75/1,90
1-year* 122/1,73
Values are n/N (%) or mean  SD. *Censored at August 10, 2011, the
not included in describing this rate.
CABG ¼ coronary artery bypass graft; MACCE ¼ major adverse cardiac aballoon pump (IABP) was inserted in 39.1% of STEMI
and 16.7% of NSTEACS patients. Rotational atherec-
tomy was undertaken in 3 (0.4%) STEMI, 160 (6.7%)
NSTEACS, and 115 (6.1%) CSA cases, and the glyco-
protein IIb/IIIa inhibitor abciximab was used in 456
(59.9%) STEMI, 660 (29.4%) NSTEACS, and 415
(23.6%) CSA patients.
Clinical outcomes. Overall, there were 1,280 (25.3%) deaths
over a total follow-up period of 11,103 patient years. The
length of follow-up was not imbalanced, and crude all-cause
mortality rates were 44.4% for STEMI, 32.1% for
NSTEACS, and 16.2% for CSA patients. Crude in-hospital
MACCE rates were highest in STEMI patients (STEMI:
27.0%, NSTEACS: 6.5%, CSA: 3.4%). After adjustment,
the risk of in-hospital MACCE was 11-fold higher
for STEMI patients and 2-fold higher for NSTEACS
patients than for CSA (STEMI aOR: 10.91, 95% CI: 7.81
to 15.24, NSTEACS aOR: 1.85, 95% CI: 1.33 to 2.59). Forse Who Received PCI, by Clinical Presentation
900
STEMI
n ¼ 784
NSTEACS
n ¼ 2,381
0 (0.0) 3/231 (1.3) 2/791 (0.3)
3 (0.2) 3/526 (0.6) 4/1,497 (0.3)
0 (1.0) 8/714 (1.1) 24/2,129 (1.1)
0 (6.2) 50/714 (7.0) 125/2,129 (5.9)
0 (0.8) 4/714 (0.6) 20/2,129 (0.9)
0 (0.4) 24/714 (3.4) 15/2,129 (0.7)
0 (0.6) 38/714 (5.3) 27/2,129 (1.3)
0 (0.2) 29/714 (4.1) 15/2,129 (0.7)
0 (0.6) 44/714 (6.2) 45/2,129 (2.1)
7 (2.0) 7/525 (1.3) 22/2,062 (1.1)
7 (0.0) 1/525 (0.2) 1/2,062 (0.1)
6 (0.2) 7/524 (1.3) 24/2,063 (1.2)
0 (0.0) 5/231 (2.2) 5/791 (0.6)
3 (0.3) 7/526 (1.3) 19/1,497 (1.3)
0 (0.0) 1/231 (0.4) 2/791 (0.3)
3 (0.1) 4/526 (0.8) 2/1,497 (0.1)
7 (0.3) 4/789 (0.6) 10/2,240 (0.5)
7 (0.3) 4/789 (0.6) 12/2,240 (0.5)
3.2 39.2  32.1 14.0  19.2
0 (1.0) 193/784 (24.6) 130/2,381 (5.5)
0 (1.4) 222/784 (28.3) 212/2,381 (8.9)
0 (4.0) 263/784 (33.6) 373/2,381 (15.7)
6 (7.0) 257/683 (37.6) 414/2,127 (19.5)
refore all PCI procedures performed after August 10, 2010, were
nd cerebrovascular event(s); other abbreviations as in Table 1.
Figure 4. Adjusted Risks for 30-Day Mortality for CSA, STEMI, and NSTEACS (Complete Case and Imputed)
The adjusted odds ratios (aOR) and 95% conﬁdence intervals (CI) for (A) chronic stable angina (CSA), (B) ST-segment elevation myocardial infarction (STEMI), and (C)
non-ST-segment elevation acute coronary syndrome (NSTEACS), were calculated using multivariate logistic regression for both complete case and pooled imputed
data. *Imputed data. MI ¼ myocardial infarction; other abbreviations as in Figure 1.
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724acute cases with cardiogenic shock, in-hospital MACCE
rates were signiﬁcantly higher, occurring in 131 (50.2%)
cases of STEMI and 38 (21.7%) NSTEACS compared with
10.8% and 5.0%, respectively, for patients without shock.
Likewise, in ventilated patients, in-hospital MACCE
occurred in 53.6% of STEMI and 24.7% of NSTEACS
patients.
Across the strata of clinical presentation, crude 30-day
and 1-year mortality rates were STEMI: 28.3% and 37.6%,
NSTEACS: 8.9% and 19.5%, and CSA: 1.4% and 7.0%,
respectively (Fig. 2). After adjustment, acute cases remained
at a signiﬁcantly elevated risk of death (30-day mortality:
STEMI aOR: 29.45, 95% CI: 19.37 to 44.80, NSTEACS
aOR: 6.45, 95% CI: 4.27 to 9.76; 1-year mortality: STEMI
aOR: 4.95, 95% CI: 4.07 to 6.02, NSTEACS aOR: 2.07,
95% CI: 1.76 to 2.43). Mortality rates in patients with
STEMI who had cardiogenic shock were higher than in
STEMI patients without shock (30 days: 52.0% vs. 11.7%, 1year: 61.1% vs. 20.9%). Figure 3 shows that for STEMI and
NSTEACS patients, the presence of cardiogenic shock was
associated with signiﬁcantly worse outcomes. In acute cases
without cardiogenic shock, the radial approach, compared
with the femoral approach, was associated with lower crude
rates of mortality, but only at 30 days (STEMI 30 days:
14.8% vs. 6.2%, 1-year: 20.8% vs. 19.4%; NSTEACS 30
days: 7.4% vs. 5.7%, 1 year: 17.0% vs. 15.8%). Table 2 shows
outcomes by clinical presentation.
Predictors of 30-day mortality. Figure 4 shows the inde-
pendent predictors of 30-day mortality by strata of clinical
presentation. For STEMI and NSTEACS, predictors were
age >80 years, pre-procedural cardiogenic shock, severe
LVSD, pre-procedural ventilation, periprocedural coronary
dissection, periprocedural shock, the use of IVUS, and the
radial approach over femoral. There was no difference in risk
of 30-day mortality by radial or femoral approach in patients
with CSA. After adjustment, the mortality beneﬁt of the
Figure 4. Continued
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725radial approach was stronger in STEMI patients without
cardiogenic shock, and not evident in NSTEACS patients
without shock (STEMI aOR: 0.38, 95% CI: 0.17 to 0.86
and NSTEACS aOR: 0.75, 95% CI: 0.49 to 1.15). Other
independent predictors of 30-day mortality were chronic
renal failure and periprocedural AMI. By contrast, inde-
pendent predictors for CSA were age >80 years and peri-
procedural coronary dissection.
Predictors of 1-year mortality. Figure 5 shows the inde-
pendent predictors of 1-year mortality by clinical presenta-
tion. For STEMI, predictors of 1-year mortality were age
>80 years, pre-procedural cardiogenic shock, severe LVSD,
pre-procedural ventilation, periprocedural coronary dissec-
tion, and periprocedural shock, For NSTEACS, the pre-
dictors were age >80 years, pre-procedural cardiogenic
shock, previous MI, chronic renal failure, severe LVSD, pre-
procedural ventilation, periprocedural AMI, periprocedural
shock, and the use of abciximab. For CSA, independent
predictors were age >80 years and the use of abciximab. ForSTEMI, NSTEACS, and CSA, the radial approach was not
a statistically signiﬁcant predictor of 1-year mortality. In
emergency patients without cardiogenic shock, the radial
over the femoral approach was not signiﬁcantly associated
with lower risk of mortality at 1-year (STEMI aOR: 0.98,
95% CI: 0.60 to 1.61 and NSTEACS aOR: 1.11, 95% CI:
0.88 to 1.41).
Sensitivity analyses. Although there was evidence for hos-
pital (level 2) effects, the use of mixed effects models did
not substantially affect the patient (level 1) estimates.
Multiple imputation of missing data made only very small
changes to point estimates generated from the models,
though in general, imputation of missing data improved
their precision.
Discussion
This is the ﬁrst whole-country comparative outcomes study
of UPLMS PCI according to clinical presentation. Our
Figure 4. Continued
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726main ﬁnding in relation to our primary aim is that after
consideration of case mix, patients who present with
STEMI or NSTEACS in the context of UPLMS PCI
have substantially higher risks of in-hospital MACCE as
well as 30-day and 1-year mortality when compared with
elective cases. Furthermore, more than 40% of patients who
presented with STEMI had evidence of cardiogenic shock,
and this was associated with a 9-fold increase in risk of
mortality at 30 days and a 5-fold increase in risk of mortality
at 1 year. Despite this, rates of 30-day all-cause mortality in
patients with STEMI or NSTEACS were lower than the
suggested benchmark of 55% (28). These ﬁndings are of
particular clinical relevance at a time when international
guidelines recommend primary angioplasty in patients with
STEMI and as complete revascularization as possible in
those with established cardiogenic shock (29,30). The
outcome data that we report in this observational study will
be of value when considering the early and longer-term riskof outcomes after PCI for patients with an UPLMS stenosis
in an elective setting.
In terms of adjuvant technologies, we have found that the
use of an IABP was high in both STEMI and NSTEACS
patients. In the light of recent trial data suggesting limited or
no outcome beneﬁt of IABP in the context of cardiogenic
shock (31), it will be interesting to see whether the use of
this device decreases in these subgroups over time. By
contrast, the use of an IVUS was lower than reported in
other studies, but when used, was associated with improved
outcomes, which is consistent with data previously published
in the context of LMS PCI (32–34). Notably, we found that
overall, the radial approach to access was associated with
better outcomes, but only at 30 days and only in STEMI
and NSTEACS patients. We also found small differences in
bleeding rates in radial versus femoral access. This ﬁnding
may be an important observation because it adds weight to
the recently reported ﬁnding that the radial access route is
Figure 5. Adjusted Risks for 1-Year Mortality Rate for CSA, STEMI, and NSTEACS (Complete Case and Imputed)
The adjusted odds ratio (aOR) and 95% Conﬁdence Interval (CI) for (A) CSA, (B) STEMI, and (C) NSTEACS, were calculated using multivariate logistic regression for both
complete case and pooled imputed data. *Imputed data. Abbreviations as in Figures 1, 2, and 4.
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727safer than femoral in STEMI patients and suggests that this
beneﬁt extends to NSTEACS patients in the real world
(28,35,36). Radial access may, however, reﬂect a less sick
population and/or more skilled operators. Beneﬁt of radial
access is no longer evident at 1 year, possibly as a result of
factors other than the index intervention that are associated
with longer-term outcomes. For example, mortality at 1 year
is more likely to be inﬂuenced by noncardiac factors than at
30 days (37). Notably, the early mortality effect interacted
signiﬁcantly with the presence of cardiogenic shock (a much
lower risk of 30-day mortality was evident in patients
without cardiogenic shock).
We identiﬁed a number of additional factors associated
with outcomes in patients treated by PCI to UPLMS. In
keeping with results from other cohort studies, STEMI
and NSTEACS patients were signiﬁcantly associated
with higher in-hospital MACCE and 30-day and 1-yearmortality compared with stable presentations (10,24). For
STEMI and NSTEACS patients, the signiﬁcant pre-
dictors of 30-day mortality were cardiogenic shock, severe
LVSD, pre-procedural ventilation, age >80 years, and
peri-procedural shock: all factors that have previously
been reported (10,11,13,23,38). For CSA, the signiﬁcant
predictors of early mortality (age >80 years and peri-
procedural coronary dissection) were superseded by age
>80 years, which independently predicted 1-year mor-
tality. Similarly, chronic renal impairment and LVSD
were not independent predictors of 1-year mortality in
elective cases, in which group increasing age remained a
strong predictor. Notably, the absolute level of 1-year
mortality in the CSA cohort was higher than expected
from previously reported data on UPLMS PCI. There is
no formal explanation available for this ﬁnding, but it is
of potential clinical relevance, and indeed bears closer
Figure 5. Continued
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728scrutiny, when some interventionalists seek to extend the
envelope for UPLMS PCI to include some patients who
are suitable for CABG procedure.
Mortality rates summarized over the 6 years of our
national study were lower than those reported by others.
Parma et al. (10) described crude 30-day mortality rates for
UPLMS PCI patients of 39.7%, and Brennan et al. (11)
reported crude in-hospital mortality rates of 2.9% for CSA
and 45.1% for emergent cases. A recent meta-analysis of
UPLMS primary PCI outcomes in patients with AMI
estimated the mean 30-day all-cause mortality rate to be
55% for patients with cardiogenic shock, which supports our
observed rate of 52% for patients with STEMI (28).
Study strengths. The strengths of this study include the
national data source that provides data in a large and un-
selected consecutive cohort of patients treated by PCI, the
depth of detail of data, and the robust tracking of mortality
by linkage of the NHS number.Study limitations. Limitations include the fact that we
were reliant on the accuracy of the data recorded from each
operator and hospital. For the patients studied, we were
not able to validate the procedural details or in-hospital
MACCE, and these may suffer from information bias. In
this paper, we presented a limited descriptive analysis on
post-procedure bleeding, and we do know that bleeding is
lower in the radial versus the femoral group; however,
detailed modeling analysis is beyond the remit of this paper
and is the subject of a separate study of the U.K. dataset
that speciﬁcally addresses these interesting and complex
issues. We cannot determine rates of repeat revasculariza-
tion in follow-up because of the lack of such information
in our dataset. We did not have sufﬁcient data ﬁelds to
calculate the EuroSCORE; nonetheless, we selected data
to adjust for case mix using a previously published PCI
outcomes model (21). We found evidence for missing data
and our underlying assumption that it was missing at
Figure 5. Continued
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729random. This allowed the multiple imputation of missing
data, which did not substantially change the model esti-
mates generated. Finally, this study has disclosed many
important associations, but cannot provide evidence for
causation.
Conclusions
National data from the BCIS registry of PCI shows that
more than one-half of patients treated with PCI to the
UPLMS present acutely. For these cases, early and longer-
term outcomes are signiﬁcantly worse than for elective cases.
Cardiogenic shock is common in STEMI patients and is
associated with a 1-in-2 risk of early mortality. The radial
approach to access was associated with improved early out-
comes in acute cases, but was not supported by lower
mortality in the longer term. Finally, 1-year mortality rates
for CSA cases approached 1 in 10, which may have a bearingon the selection of elective cases for UPLMS PCI who are
also suitable for CABG procedure.
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